The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study

PMCID: PMC12178961

PMID: 40536732

DOI: 10.1007/s00432-025-06246-2

Journal: Journal of cancer research and clinical oncology

Publication Date: 2025-6-19

Authors: Schneeweiss A, Fasching PA, Thill M, van Mackelenbergh M, Marme F, et al.

Key Points

• Nab-paclitaxel demonstrated consistent efficacy across multiple treatment lines in advanced breast cancer
• Median progression-free survival of 6.0 months (95% CI: 5.6–6.9) with a manageable safety profile
• Brain metastases significantly impact treatment outcomes, warranting careful patient selection and monitoring

Summary

This non-interventional, real-world study evaluated nab-paclitaxel in 432 patients with advanced breast cancer, primarily focusing on HER2-negative disease. The study examined treatment outcomes across multiple therapy lines, with 30.1% of patients receiving first-line treatment and 48.3% in third or later lines. The patient population predominantly consisted of HR-negative (79.6%) and HER2-negative (94.2%) breast cancer patients.

The clinical outcomes revealed a median progression-free survival (PFS) of 6.0 months and median overall survival (OS) of 15.3 months. Notably, patients with brain metastases experienced the shortest PFS at 3.0 months. The safety profile was manageable, with adverse events occurring in 83.1% of patients, though high-grade events were rare (< 8%). Quality of life remained stable throughout treatment, suggesting minimal treatment-related deterioration in patient well-being.